论文部分内容阅读
目的:分析研究肺癌患者血清肿瘤标志物检测的方法以及应用价值,为临床提供依据。方法:选取2014年1月到2015年1月肺癌患者资料50例以及肺部非肿瘤性疾病患者资料50例实施回顾性分析,对两组患者治疗之前以及治疗之后的血清癌胚抗原、神经元特异性烯醇化酶以及细胞角质蛋白19片段水平进行检测,将检测结果进行统计学分析。结果:肺癌组患者的血清癌胚抗原、神经元特异性烯醇化酶以及细胞角质蛋白19片段水平显著高于非肺癌组患者(P<0.05),具有统计学意义,其中血清癌胚抗原水平最高,小细胞癌患者血清神经元特异性烯醇化酶水平最高,鳞癌患者血清细胞角质蛋白19片段水平最高;化疗有效和化疗无效患者之间的血清肿瘤标志物比较存在明显的差异(P<0.05),具有统计学意义。结论:对肺癌患者进行血清癌胚抗原、神经元特异性烯醇化酶以及细胞角质蛋白19片段水平检测可以帮助对肿瘤细胞类型的判断,患者化疗之前以及化疗之后的血清水平改变情况和治疗效果密切相关。
Objective: To analyze the method of detecting tumor markers in patients with lung cancer and its clinical value. Methods: A retrospective analysis was performed on 50 patients with lung cancer and 50 patients with lung non-neoplastic disease from January 2014 to January 2015. The serum levels of carcinoembryonic antigen, neuron Specific enolase and cytokeratin 19 fragment levels were detected, the test results were statistically analyzed. Results: The levels of serum carcinoembryonic antigen, neuron specific enolase and keratin 19 in patients with lung cancer were significantly higher than those in non-lung cancer patients (P <0.05), with statistical significance, with the highest level of serum carcinoembryonic antigen , The level of serum neuron-specific enolase in patients with small cell carcinoma was the highest, and the level of serum keratin 19 in patients with squamous cell carcinoma was the highest. There were significant differences in serum tumor markers between chemotherapy-ineffective and chemotherapy-ineffective patients (P <0.05 ),has statistical significane. Conclusion: The detection of serum carcinoembryonic antigen, neuron-specific enolase and cytokeratin 19 fragments in lung cancer patients can help to determine the type of tumor cells, the changes of serum levels before chemotherapy and after chemotherapy, and the treatment effect Related.